Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767

Karilyn Gower, Press Officer
w. (202) 588-7779

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog

Follow us on Twitter


Jan. 10, 2013

FDA Should Reject Dangerous Diabetes Medication, Public Citizen Tells Advisory Committee

Canagliflozin, Part of a New Class of Diabetes Drugs, Presents Too Many Risks to Patients

WASHINGTON, D.C. – The U.S. Food and Drug Administration (FDA) should not approve the diabetes drug canagliflozin because it could significantly harm patients and does not present significant benefit over current medications, Public Citizen said today.

In testimony today before an FDA advisory committee, director of Public Citizen’s Health Research Group Dr. Sidney Wolfe warned that the new drug presents an unsafe increase of risk for low blood pressure symptoms, adverse cardiac events, and genital and urinary infections. He urged the panel to recognize that in no way do these risks outweigh potential benefit over existing diabetes treatments.

Canagliflozin is part of a new class of diabetes drugs called sodium glucose co-transporter-2 inhibitors that work by blocking re-absorption of glucose by the kidney and increasing glucose excretion in the urine to lower blood sugar. This results in a large loss of sugary fluids. Traditional diabetes treatments typically work by improving insulin secretion or insulin sensitivity.

“The fact that the drug works by a uniquely new mechanism to lower blood sugar has not spared of a whole set of unique new risks,” said Wolfe. “The FDA has previously made too many mistakes in approving drugs, including those for diabetes, with no unique clinical benefits and unique risks. The agency shouldn’t approve this one.”

To read today’s testimony, visit: http://www.citizen.org/hrg2091.


Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


You can support the fight for greater government and corporate accountability through a donation to either Public Citizen, Inc., or Public Citizen Foundation, Inc.

Public Citizen lobbies Congress and federal agencies to advance Public Citizen’s mission of advancing government and corporate accountability. When you make a contribution to Public Citizen, you become a member of Public Citizen, showing your support and entitling you to benefits such as Public Citizen News. Contributions to Public Citizen are not tax-deductible.

Public Citizen Foundation focuses on research, public education, and litigation in support of our mission. By law, the Foundation can engage in only very limited lobbying. Contributions to Public Citizen Foundation are tax-deductible.